Enanta Pharmaceuticals (9EP) Stock Statistics & Valuation Metrics

Enanta Pharmaceuticals has a market cap or net worth of EUR 278.37M. The enterprise value is EUR 416.67M.

Market Cap

EUR 278.37M

Enterprise Value

EUR 416.67M

Enanta Pharmaceuticals has 29,125,402 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

29,125,402

Owned by Insiders

4.74%

Owned by Institutions

25.74%

Enanta Pharmaceuticals’s return on equity (ROE) is -1.27 and return on invested capital (ROIC) is -31.44%.

Return on Equity (ROE)

-1.27

Return on Assets (ROA)

-0.29

Return on Invested Capital (ROIC)

-31.44%

Return on Capital Employed (ROCE)

-0.37

Revenue Per Employee

544.37K

Profits Per Employee

-682.41K

Employee Count

120

Asset Turnover

0.23

Inventory Turnover

0.00

The current PE Ratio of Enanta Pharmaceuticals is -4.44. Enanta Pharmaceuticals’s PEG ratio is -0.07.

PE Ratio

-4.44

PS Ratio

4.78

PB Ratio

3.08

Price to FCF

-8.44

Price to Operating Cash Flow

-8.82

PEG Ratio

-0.07

In the last 12 months, Enanta Pharmaceuticals had revenue of 65.32M and earned -81.89M in profits. Earnings per share was -3.84.

Revenue

65.32M

Gross Profit

60.74M

Operating Income

-85.35M

Pretax Income

-83.55M

Net Income

-81.89M

EBITDA

-70.78M

Earnings Per Share (EPS)

-3.84

In the last 12 months, operating cash flow was -35.32M and capital expenditures -1.62M, giving a free cash flow of -36.94M billion.

Operating Cash Flow

-35.32M

Free Cash Flow

-36.94M

Free Cash Flow per Share

-1.27

Enanta Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-11.84%

Earnings Yield

-20.30%

Beta

1.11

52-Week Price Change

0.53%

50-Day Moving Average

10.98

200-Day Moving Average

11.32

Relative Strength Index (RSI)

36.10

Average Volume (3m)

―

Enanta Pharmaceuticals upcoming earnings date is Nov 16, 2026, After Close (Not Confirmed).

Last Earnings Date

Aug 10, 2026

Next Earnings Date

Nov 16, 2026

Ex-Dividend Date

―

Enanta Pharmaceuticals as a current ratio of 4.21, with Debt / Equity ratio of 310.67%

Current Ratio

4.21

Quick Ratio

4.21

Debt to Market Cap

0.56

Net Debt to EBITDA

-2.38

Interest Coverage Ratio

-11.11

In the past 12 months, Enanta Pharmaceuticals has paid -1.66M in taxes.

Income Tax

-1.66M

Effective Tax Rate

0.02

Enanta Pharmaceuticals EV to EBITDA ratio is -7.38, with an EV/FCF ratio of -9.05.

EV to Sales

5.12

EV to EBITDA

-7.38

EV to Free Cash Flow

-9.05

EV to Operating Cash Flow

-9.46

Enanta Pharmaceuticals has EUR 189.51M in cash and marketable securities with EUR 55.66M in debt, giving a net cash position of EUR 133.85M billion.

Cash & Marketable Securities

EUR 189.51M

Total Debt

EUR 55.66M

Net Cash

EUR 133.85M

Net Cash Per Share

EUR 4.60

Tangible Book Value Per Share

EUR 3.47

Gross margin is 98.15%, with operating margin of -89.99%, and net profit margin of -96.89%.

Gross Margin

98.15%

Operating Margin

-89.99%

Pretax Margin

-96.74%

Net Profit Margin

-96.89%

EBITDA Margin

-69.43%

EBIT Margin

-76.95%

The average price target for Enanta Pharmaceuticals is EUR 17.86, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

EUR 17.86

Price Target Upside

89.97% Upside

Analyst Consensus

Moderate Buy

Analyst Count

1

Revenue Growth Forecast

-6.02%

EPS Growth Forecast

48.10%

Smart Score

4

AI Score

―